Resistin Levels in Morbid Obese Patients Following the Biliopancreatic Diversion Surgery

D. A. de Luis; M. C. Terroba; L. Cuellar; R. Conde; D. Primo; R. Aller; M. G. Sagrado; O. Izaola

doi:10.1055/s-0030-1270529

Hormone and Metabolic Research, Table of Contents

Horm Metab Res 2011; 43(3): 205-208
DOI: 10.1055/s-0030-1270529

Humans, Clinical

Resistin Levels in Morbid Obese Patients Following the Biliopancreatic Diversion Surgery

D. A. de Luis¹ , M. C. Terroba¹ , L. Cuellar¹ , R. Conde¹ , D. Primo¹ , R. Aller¹ , M. G. Sagrado¹ , O. Izaola¹

¹Center of Investigation of Endocrinology and Nutrition, Medicine School, Unit of Investigation, Surgical Department, and Endocrinology Department, Hospital Rio Hortega, University of Valladolid, Valladolid, Spain

Abstract

Previous studies addressing the changes of resistin concentrations in morbidly obese patients after bariatric surgery have yielded conflicting results. The purpose of the present study was to investigate the changes in serum resistin levels 1 year after biliopancreatic diversion in morbidly obese patients without diabetes mellitus. A cohort of 39 morbidly obese patients without diabetes mellitus was operated. Biochemical and anthropometric evaluation were realized at basal visit and at each visit. The frequency of patients with hypertension and hyperlipidemia was recorded at each visit. Overall the mean patient age was 44.8±14.1, and the mean preoperative BMI was 47.3±6.5 kg/m². After one year of surgery, a significant decrease was observed in BMI, weight, waist circumference, fat mass, blood pressure, total cholesterol, LDL cholesterol, and triglyceride levels. Resistin levels did not change after surgery (5.61±1.93 ng/ml vs. 6.41±3.58 ng/ml; ns). Correlation analysis showed a positive association between basal resistin and weight (r=0.68, p<0.01) and fat mass (r=0.65, p<0.05). Resistin concentrations did not change after massive weight loss with biliopancreatic diversion in morbid obese patients without diabetes mellitus.

Key words

biliopancreatic diversion - resistin - morbid obesity - surgery

Full Text

References

1 Aranceta J, Perez Rodrigo C, Serra Majem L. Prevalencia de la obesidad en España: estudio SEEDO 97. Med Clin (Barc). 1998; 111 441-445
2 de luis DA, Aller R, Izaola O, Pacheco D. Early clinical and surgical results of biliopancreatic diversion. Obes Surg. 2005; 15 799-802
3 Scopinaro N, Adami GF, Marinari GM. Biliopancreatic diversion. World J Surg. 1998; 22 936-946
4 Matsuda M, Shimomura I, Sata M. Role of adiponectin in preventing vascular stenosis. The missing link of adipo-vascular axis. J Biol Chem. 2002; 277 37487-37491
5 Steppan CM, Bailey ST, Bhat S, Brown EJ. The hormone resistin links obesity to diabetes. Nature. 2001; 409 307-312
6 Satoh H, Nguyen MT, Miles PD, Immamura T, Usui I, Olefsky JM. Adenovirus-mediated chronic hyper resistinemia leads to in vivo insulin resistance in normal rats. J Clin Inves. 2004; 114 224-231
7 Steppan CM, Lazar MA. The current biology of resistin. J Intern Med. 2004; 255 439-447
8 Sato N, Kobayashi K, Inoguchi T, Sonoda N, Immamura M, Sekiguchi N, Nakashima N, Nawata H. Adenovirus-mediated high expression of resistin causes dyslipemia in mice. Endocrinol. 2005; 146 273-279
9 Muse ED, Obici S, Bhanot S, Monia BP, McKay RA, Rajala MW, Scherr PE, Rossetti L. Role of resistin in diet-induced hepatic insulin resistance. J Clin Invest. 2004; 114 232-239
10 Patel L, Buckles AC, Kinghorn IJ, Murdock PR, Holbrook JD. Resistin is expressed in human macrophages and directly regulated by PPAR gamma activated receptor gamma action in humans. Biochem Biophys Res Commun. 2003; 300 472-476
11 Pagano C, Marin O, Calcagno A, Schiappelli P, Pilon C, Milan G, Bertelli M, Fanin E. Increased serum resistin in adults with Prader Willi syndrome is related to obesity and not to insulin resistance. J Clin Endocrinol Metab. 2005; 90 4335-4340
12 Burnett MS, Devaney JM, Adenika RJ, Lindsay R, Howard BV. Cross-sectional associations of resistin, coronary heart disease and insulin resistance. J Clin Endocr Metab. 2006; 91 64-68
13 De Luis DA, Gonzalez Sagrado M, Conde R, Aller R, Izaola O. Relation of resistin levels with cardiovascular risk factors and insulin resistance in non-diabetes obese patients. Diab Res Clin Res. 2009; 84 174-178
14 Zou CC, Liang L, Hong F, Fu JF, Zhao ZY. Serum adiponectin, resistin levels and non alcoholic fatty liver disease in obese children. Endocrine J. 2005; 52 519-524
15 Moschen AR, Molnar C, Wolf A, Weiss H, Graziadei I, Kaser S, Ebenbichler CF, Stadlmann S, Moser P, Till H. Effects of weight loss induced by bariatric surgery on hepatic adipocytokine expression. J Hepatol. 2009; 51 765-777
16 Whitson B, Leslie D, Kellog T, Maddaus M, Buchwald H, Billington C, Ikramuddin S. Adipokine response in diabetics and nondiabetes following the roux en y gastric bypass: a preliminary study. Journal of Surgery Research. 2007; 142 295-300
17 Argentou M, Tiniakos DG, Karanikolas M, Melachrinou M, Makri MG, Kittas C, Kalfarentzos F. Adipokine serum levels are related to liver histology in severely obese patients undergoing bariatric surgery. Obes Surg. 2009; 19 1313-1323
18 Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP). . Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA. 2001; 285 2486-2487
19 Standards of diabetes mellitus, American Diabetes Association. . Diabetes Care. 2007; 30 s4-s41
20 Pfutzner A, Langenfeld M, Kunt T, Lobig M, Forst T. Evaluation of human resistin assays with serum from patients with type 2 diabetes and different degrees of insulin resistance. Clin Lab. 2003; 49 571-576
21 Iqbal N, Seshadri P, Stern L, Loh J, Kundu S, Jafar T, Samaha FE. Serum resistin is not associated with obesity or insulin resistance in humans. European Rev Med Pharmacol Sci. 2005; 9 161-165
22 Vendrell J, Broch M, Vilarrasa N. Resistin, adiponectin, ghrelin, leptin and proinflammatory cytokines: relationships in obesity. Obes Res. 2004; 12 962
23 Santoro S, Malzoni CE, Velhote MC, Milleo FQ, Santo MA, Klajner S, Daminai D. Digestive adaptation with intestinal reserve: a neuroendocrine based operation for morbid obesity. Obes Surg. 2006; 16 1371-1379
24 Harrison SA, Fecht W, Brunt EM, Neuschwander-Tetri BA. Orlistat for overweight subjects with nonalcoholic steatohepatitis: a randomized, prospective trial. Hepatology. 2009; 49 80-86
25 Busetto L, BAsseto F, Zocchi M, Zuliani F, Nolli ML, Pigozzo S, Coin A, Mazza M, Sergi G, Mazzoleni F. The effects of the surgical removal of subcutaneous adipose tissue on energy expenditure and adipocytokine concentrations in obese women. Nutr Metab Cardiovasc Dis. 2008; 18 112-120

Correspondence

Dr. D. A. de Luis

Associate Professor of

Endocrinology and Nutrition

Executive Director of Institute

of Endocrinology and Nutrition

Medicine School

Valladolid University

C/ Los perales 16 Simancas

47130 Valladolid

Spain

Phone: +34/98/3420 400

Fax: +34/98/3331 566

Email: dadluis@yahoo.es